Our Products

VOWST (fecal microbiota spores, live-brpk), formerly SER-109, is the first and only FDA-approved orally administered microbiota-based therapeutic indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).

Limitations of use: VOWST is not indicated for the treatment of CDI.

The most common adverse reactions (reported in 5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%). To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.
See below for Full Prescribing Information.

Full Prescribing Information

Patient Information

Visit www.VOWST.com to learn more.

Medical Information Inquiries for U.S. Healthcare Professionals: medicalinformation@aimmune.com or 833-246-2566.